CIPLA Ltd - Healthy Performance on All Parameters
The company’s US revenue stood at $230 Mn (vs. exp $220 Mn) and was led by improvement in the base business pricing and higher MS in Lenotirade,...
173 Views
Pharma Sector: Q3FY24 Review
EBITDA margin witnessed a healthy improvement of 220bps YoY and 55bps QoQ, attributed to normalizing cost inflation and stabilizing prices.
316 Views
Axis Research Scorecard Report for Jan 2024
Post Budget Analysis and Stock Ideas: It gives us immense joy to announce our Post Budget Analysis and Stock Ideas for 2024-25.
308 Views
Pharma Sector: Q2FY24 Review
In Q2FY24, the Pharma Coverage universe posted robust revenue growth of 14.3%/1.7% YoY/QoQ on account of volume rampup, new launches (especially...
304 Views
Axis Research Scorecard Report for Oct 2023
Our POW calls delivered an excellent Monthly strike rate of 84% in Oct’23. Calls that successfully achieved their target were Nestle India (~10%),...
354 Views